These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15293890)

  • 1. Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women.
    Morgante G; Farina M; Cianci A; La Marca A; Petraglia F; De Leo V
    Gynecol Endocrinol; 2004 Apr; 18(4):194-8. PubMed ID: 15293890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM; Quail DC; Levy-Frebault J; Aguas F; Kosian K; Garrido L; Bosio-Le Goux B; Saráchaga M; Graebe A; Niño AJ; Nickelsen T
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
    Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D
    Menopause; 2004; 11(2):167-75. PubMed ID: 15021446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
    Gallagher JC; Shi H; Mirkin S; Chines AA
    Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective estrogen modulators in menopause.
    Gambacciani M
    Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
    Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
    Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.
    Komi J; Lankinen KS; Härkönen P; DeGregorio MW; Voipio S; Kivinen S; Tuimala R; Vihtamäki T; Vihko K; Ylikorkala O; Erkkola R
    Menopause; 2005 Mar; 12(2):202-9. PubMed ID: 15772568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
    Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD
    Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.
    Valiati B; Capp E; Edelweiss MI; de Freitas FM; Wender MC
    Maturitas; 2009 Jan; 62(1):81-4. PubMed ID: 19097715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women.
    Lasco A; Cannavò S; Gaudio A; Morabito N; Basile G; Nicita-Mauro V; Frisina N
    Eur J Endocrinol; 2002 Oct; 147(4):461-5. PubMed ID: 12370106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
    Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
    Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes.
    Carretti N; Florio P; Reis FM; Comai S; Bertazzo A; Petraglia F
    Climacteric; 2010 Apr; 13(2):141-6. PubMed ID: 20082603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
    Cohen FJ; Lu Y
    Maturitas; 2000 Jan; 34(1):65-73. PubMed ID: 10687884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
    Delmas PD; Bjarnason NH; Mitlak BH; Ravoux AC; Shah AS; Huster WJ; Draper M; Christiansen C
    N Engl J Med; 1997 Dec; 337(23):1641-7. PubMed ID: 9385122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women.
    Neele SJ; Evertz R; De Valk-De Roo G; Roos JC; Netelenbos JC
    Bone; 2002 Apr; 30(4):599-603. PubMed ID: 11934652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of raloxifene in postmenopausal women.
    Agnusdei D
    Eur J Obstet Gynecol Reprod Biol; 1999 Jul; 85(1):43-6. PubMed ID: 10428320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
    Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
    Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.